Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprocitentan in Uncontrolled Hypertension and CKD
NCT04162366Phase 3Withdrawn
- Sponsor
- Idorsia
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) comparing Aprocitentan 25 mg with Placebo (2 arms). Primary endpoint: Change from Baseline in mean trough sitting systolic blood pressure at 4 weeks. Planned start Jan 2020; status: withdrawn.
02
Drugs
aprocitentan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04162366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162366.